文献速递消化道肿瘤放疗放疗物理与技术

碳离子放疗联合系统治疗强度与代谢反应在局部晚期胰腺癌中的研究

Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiation Therapy for Locally Advanced Pancreatic Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-09-10

回顾性分析96例局部晚期胰腺癌患者接受碳离子放疗联合同步系统治疗的资料,按同步化疗强度分为单药、双药和三药组,各组在局部无失败生存、无远处转移生存和总生存上无显著差异;探索性影像亚组显示代谢反应与局部控制改善相关,而形态学反应无关。

要点

  • 同步化疗强度分组间局部无失败生存、无远处转移生存和总生存均无显著差异。
  • 标准化疗时长与次优时长相比,无远处转移生存无显著关联(HR 0.68,95%CI 0.31-1.50)。

核心结论

  • 同步化疗强度与局部无失败生存、无远处转移生存和总生存无显著关联。
  • 探索性分析未提供确凿证据表明更大累积系统治疗暴露改善临床结局。
  • 18F-FDG PET代谢反应对局部控制显示潜在预后价值。

研究设计与样本

  • 回顾性综述96例接受碳离子放疗联合同步系统治疗的局部晚期胰腺癌患者。
  • 按同步化疗强度分为单药、双药和三药组。
  • 采用7个月landmark分析评估累积系统治疗暴露。
  • 影像亚组定义代谢反应为最大标准化摄取值降低≥50%或治疗后18F-FDG PET代谢失活。

主要发现

  • 同步化疗强度各组间局部无失败生存、无远处转移生存和总生存无统计学显著差异。
  • landmark分析中标准化疗时长与次优时长相比无远处转移生存无显著关联(HR 0.68;95%CI 0.31-1.50)。
  • 调整后估计相似但不精确(HR 0.65;95%CI 0.29-1.44)。
  • 总体队列中位总生存为29.7个月。

关键数值与推荐

  • 代谢反应定义为最大标准化摄取值降低≥50%或治疗后18F-FDG PET代谢失活。
  • landmark分析时间点为7个月。

临床怎么用

  • 碳离子放疗期间同步系统治疗强度选择需个体化,当前证据不支持常规增加强度。
  • 18F-FDG PET代谢反应可作为局部控制的潜在预后标志物供前瞻性验证。

局限性

  • 回顾性队列设计。
  • 探索性分析样本量有限,估计不精确。
  • 代谢反应分析为探索性影像亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Carbon-ion radiation therapy (CIRT) provides effective local control for locally advanced pancreatic cancer, but the optimal integration of systemic therapy remains uncertain. We evaluated the associations of concurrent chemotherapy intensity and cumulative systemic therapy exposure with clinical outcomes and explored the prognostic value of metabolic versus morphologic response. METHODS AND MATERIALS: We retrospectively reviewed 96 patients with locally advanced pancreatic cancer treated with CIRT and concurrent systemic therapy. Patients were stratified by concurrent chemotherapy intensity into single-agent, doublet, and triplet groups. An exploratory 7-month landmark analysis with endpoint-specific eligibility evaluated cumulative systemic therapy exposure. In the imaging substudy, metabolic response was defined as ≥50% reduction in maximum standardized uptake value or metabolic inactivation on post-treatment 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) (PET/computed tomography or PET/magnetic resonance imaging). RESULTS: No statistically significant differences in local failure-free survival, distant metastasis-free survival (DMFS), or overall survival (OS) were observed across concurrent chemotherapy intensity groups. In the landmark analysis, standard-duration systemic therapy was not significantly associated with DMFS compared with suboptimal-duration therapy (hazard ratio, 0.68; 95% CI, 0.31-1.50). The adjusted estimate was similar but remained imprecise (hazard ratio, 0.65; 95% CI, 0.29-1.44). In the exploratory imaging substudy, metabolic response was associated with improved local control (P = .013), whereas morphologic response was not. Median OS for the overall cohort was 29.7 months. CONCLUSIONS: Concurrent chemotherapy intensity was not significantly associated with local failure-free survival, DMFS, or OS in this retrospective cohort. Exploratory analyses provided no conclusive evidence that greater cumulative systemic therapy exposure improved clinical outcomes. These findings support prospective evaluation of risk-adapted concurrent systemic therapy during CIRT. 18F-FDG PET metabolic response showed potential prognostic value for local control, supporting its prospective validation as a response biomarker.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ho IW, Lai IC, Lin KH, et al. Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiation Therapy for Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 42722206. doi:10.1016/j.ijrobp.2026.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。